Clinical Trials in Maryland

Showing 18921-18940 of 23,284 trials

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

NCT00373191

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at the effects of surgery, radiation therapy, chemotherapy, and hormone therapy on biomarkers in women with stage I, stage II, stage III breast cancer, or ductal carcinoma in situ that can be removed by surgery.

Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35 participantsStarted May 2006

Baltimore, Maryland, United States

COMPLETEDPhase 219 miles

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664

The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks

Melanoma

Bristol-Myers Squibb158 participantsStarted Mar 2008

Los Angeles, California, United States • New Haven, Connecticut, United States • Park Ridge, Illinois, United States +29 more locations

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

Phase II, 2nd Line Melanoma - RAND Monotherapy

Find Trials by Condition in Maryland

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Ph IIA Study (SOC +/- NS5B)

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

PoC in Rheumatoid Arthritis With Methotrexate

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

A Study of AZD4901 in Females With Polycystic Ovary Syndrome